data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Credit Cards
Crypto
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Free Stock Reports

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Government Trades

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Kazia Therapeutics

(NASDAQ:KZIA)

Intraday

$0.3887

0.0239[6.55%]

After-Hours

$0.3887

0[0.00%]

Perks Buy Compare Brokers

$0.3887

0.0239[6.55%]

At close: Apr 26

$0.3887

0[0.00%]

After Hours: 4:35PM EDT

Overview News Earnings Guidance Dividends Analyst Ratings Insider Trades Short Interest

Latest News for Kazia Therapeutics Stock (NASDAQ:KZIA)

Kazia Therapeutics Stock (NASDAQ: KZIA)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Friday, April 19, 2024

Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time
Benzinga Newsdesk - Apr 19, 2024, 4:42PM

Friday, April 12, 2024

Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Avi Kapoor - Apr 12, 2024, 5:32AM

Friday, April 05, 2024

Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Avi Kapoor - Apr 5, 2024, 1:06PM

Thursday, March 21, 2024

Kazia Therapeutics Licenses Paxalisib To Sovargen For Intractable Seizures In Rare Central Nervous System Diseases
Benzinga Newsdesk - Mar 21, 2024, 8:54AM

Wednesday, March 13, 2024

Kazia Presents Data At AACR Annual Meeting
Benzinga Newsdesk - Mar 13, 2024, 8:10AM

Monday, February 26, 2024

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Feb 26, 2024, 4:31PM

Friday, February 23, 2024

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Feb 23, 2024, 8:06AM

Wednesday, February 21, 2024

What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?
Vandana Singh - Feb 21, 2024, 1:58PM
12 Health Care Stocks Moving In Wednesday's Intraday Session
Benzinga Insights - Feb 21, 2024, 12:31PM
Kazia Therapeutics shares are trading lower, after initally spiking higher, amid increased volatility in the stock after the company announced the early conclusion of the Phase 1 Paxalisib trial in solid tumors after reaching the primary endpoint.
Benzinga Newsdesk - Feb 21, 2024, 11:19AM
Kazia Therapeutics shares are trading higher after the company reported early conclusion of Phase 1 Paxalisib trial in solid tumors after reaching primary endpoint.
Benzinga Newsdesk - Feb 21, 2024, 7:42AM
Kazia Therapeutics Announced The Early Conclusion Based On Safety And Clinical Response Findings Observed To Date From A Two-part Phase 1 Trial Of Paxalisib With Radiation Therapy For PI3K Pathway Mutation Brain Metastases From Solid Tumors
Benzinga Newsdesk - Feb 21, 2024, 7:40AM

Friday, February 16, 2024

12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga Insights - Feb 16, 2024, 4:31PM

Wednesday, February 07, 2024

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Feb 7, 2024, 8:06AM

Thursday, January 25, 2024

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Jan 25, 2024, 8:06AM

Wednesday, January 24, 2024

12 Health Care Stocks Moving In Wednesday's After-Market Session
Benzinga Insights - Jan 24, 2024, 4:31PM

Monday, January 22, 2024

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Jan 22, 2024, 4:31PM

Saturday, December 16, 2023

Kazia Therapeutics Filed Friday For Shelf Of Up To 591,697 American Depositary Shares By Selling Stockholder
Charles Gross - Dec 16, 2023, 8:02AM

Friday, December 08, 2023

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights - Dec 8, 2023, 12:31PM

Friday, December 01, 2023

12 Health Care Stocks Moving In Friday's Pre-Market Session
Benzinga Insights - Dec 1, 2023, 8:06AM
Kazia Therapeutics Announces $2 Million Registered Direct Offering, Closing Of The Offering Is Expected To Occur On Or About December 5, 2023
Benzinga Newsdesk - Dec 1, 2023, 8:02AM

Wednesday, November 29, 2023

Kazia Therapeutics Signs Non-Binding Letter Of Intent To Develop And Commercialize Pharmaceutical Product Containing Paxalisib Outside Of Oncology
Benzinga Newsdesk - Nov 29, 2023, 7:06AM

Monday, November 27, 2023

12 Health Care Stocks Moving In Monday's Intraday Session
Benzinga Insights - Nov 27, 2023, 12:30PM

Monday, November 20, 2023

Met Primary Endpoint, Nearly Doubling Svr35 Response Rate That It Is Not In Compliance With The Minimum Bid Price Requirement Set Forth In The Nasdaq Capital Market's Rules For Continued Listing
Benzinga Newsdesk - Nov 20, 2023, 4:37PM

Wednesday, November 15, 2023

Kazia Announces The Release Of PNOC022 Clinical Study Abstract Highlighting Paxalisib In Diffuse Midline Glioma Patients Ahead Of The Society Of Neuro-Oncology 2023 Annual Meeting
Benzinga Newsdesk - Nov 15, 2023, 8:35AM

Monday, November 13, 2023

Earlier: Securities Of Kazia Therapeutics Will Be Suspended From Quotation Immediately Under Listing Rule 17.2, At The Request Of KZA, To Facilitate Its Removal From The Official List Of ASX Limited
Charles Gross - Nov 13, 2023, 4:39AM

Friday, November 10, 2023

Kazia Therapeutics Announces The Publication In Molecular Cancer Therapeutics Highlighting Paxalisib Preclinical Data Stemming From The Research Collaboration With The Huntsman Cancer Institute At The University Of Utah
Benzinga Newsdesk - Nov 10, 2023, 7:06AM

Thursday, November 09, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Nov 9, 2023, 8:06AM

Monday, November 06, 2023

12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga Insights - Nov 6, 2023, 8:06AM

Friday, November 03, 2023

12 Health Care Stocks Moving In Friday's Intraday Session
Benzinga Insights - Nov 3, 2023, 1:31PM

Wednesday, November 01, 2023

Kazia Therapeutics Announced A Preliminary Update From The Ongoing Investigator-initiated Phase 2 Clinical Trial Of Paxalisib As Monotherapy Treatment In Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma
Benzinga Newsdesk - Nov 1, 2023, 7:30AM

Monday, October 23, 2023

Kazia Therapeutics Presents Selected Clinical Data From Ongoing Phase 1 Clinical Trial Evaluating EVT801 In Patients With Advanced Solid Tumours
Benzinga Newsdesk - Oct 23, 2023, 7:54AM

Wednesday, October 11, 2023

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Benzinga Insights - Oct 11, 2023, 9:06AM

Tuesday, October 10, 2023

Kazia Therapeutics Earlier Announced Its Intention To De-list From The Australian Securities Exchange
Charles Gross - Oct 10, 2023, 8:39PM

Friday, October 06, 2023

Kazia Therapeutics Shares Were Halted Late Thursday Pending An Announcement By Kazia Regarding The Proposed Trading Solely On Nasdaq And Proposed Delisting Of The Company's Securities From ASX
Charles Gross - Oct 6, 2023, 4:47AM

Thursday, August 31, 2023

12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga Insights - Aug 31, 2023, 9:06AM

Monday, July 10, 2023

Bank of New York Mellon Increased Stake in Kazia Therapeutics From 32.16% On April 5, 2023 To 36..21% On July 7, 2023
Charles Gross - Jul 10, 2023, 7:12PM

Thursday, July 06, 2023

What's Going On With Kazia Therapeutics Stock Today?
Adam Eckert - Jul 6, 2023, 9:41AM
Kazia Therapeutics shares are trading higher after the company announced it received FDA Fast Track Designation for its lead program, paxalisib.
Benzinga Newsdesk - Jul 6, 2023, 8:29AM
Market-Moving News for July 6th
Benzinga Newsdesk - Jul 6, 2023, 8:18AM
Kazia Therapeutics Says Its Lead Program, Paxalisib, Has Secured Fast Track Designation From FDA
Benzinga Newsdesk - Jul 6, 2023, 7:02AM

Thursday, June 08, 2023

Kazia Therapeutics Late Wednesday Announced Phase II Clinical Study To Investigate Paxalisib In Recurrent/Progressive IDH-Mutant Grade 2 & 3 Glioma
Charles Gross - Jun 8, 2023, 5:23AM

Sunday, April 30, 2023

Kazia Therapeutics Announced Dr John Friend Named CEO, Succeeding Dr James Garner
Charles Gross - Apr 30, 2023, 6:20PM

Tuesday, April 18, 2023

Kazia Shares Move Higher, Traders Circulate Report Titled 'PI3K/mTOR Is A Therapeutically Targetable Genetic Dependency In Diffuse Intrinsic Pontine Glioma'; Report Mentions Kazia Contributed Project Funding Supporting Animal Studies Outlined
Benzinga Newsdesk - Apr 18, 2023, 1:31PM

Friday, April 14, 2023

Kazia Announced Earlier It Regained Compliance With Nasdaq Minimum Bid Price Requirement
Charles Gross - Apr 14, 2023, 5:31AM

Tuesday, April 11, 2023

Benzinga's Top Ratings Upgrades, Downgrades For April 11, 2023
Benzinga Insights - Apr 11, 2023, 11:00AM
HC Wainwright & Co. Upgrades Kazia Therapeutics to Buy, Announces $2 Price Target
Benzinga Newsdesk - Apr 11, 2023, 6:18AM

Tuesday, April 04, 2023

Why AMC Entertainment Holdings Shares Are Trading Lower By 25%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Apr 4, 2023, 8:04AM

Tuesday, March 07, 2023

12 Health Care Stocks Moving In Tuesday's After-Market Session
Benzinga Insights - Mar 7, 2023, 4:31PM
Kazia Therapeutics Announced Monday, Clinical Collaboration For Australian Phase II Precision Medicine Study Of Paxalisib In Childhood Cancers
Charles Gross - Mar 7, 2023, 4:47AM

Create a Watchlist

FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.

People Also Watch

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2024 Benzinga | All Rights Reserved